This is a video synopsis/summary of a panel discussion involving Ahmed Obeidat, MD, PhD; Riley Bove, MD; Stephen Krieger, MD; and Erin Longbrake, MD, PhD.

The conversation delves into the idea of personalized medicine in multiple sclerosis (MS) treatment, focusing on factors beyond inflammatory activity. Biomarkers, such as neurofilament light chain (NFL) and glial fibrillary acidic protein (GFAP), are discussed as potential indicators of disease progression and treatment response. However, in older populations, where clinical trial data may be lacking, personalized treatment decisions become even more crucial.

Shared decision-making is highlighted as a collaborative process between doctors and patients, where individual preferences and risks are carefully considered. Patients' voices are integral to treatment decisions, especially when they express reluctance towards certain therapies. Hypothetical scenarios are proposed to help patients envision potential outcomes and make informed choices about treatment.

The importance of empowering patients with knowledge and understanding is emphasized, enabling them to actively participate in decisions about their care. By incorporating patient perspectives and clinical expertise, a personalized approach to MS treatment can optimize outcomes and enhance patients' quality of life.

Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.